|MDACC Study No:||2010-0065 (clinicaltrials.gov NCT No: NCT01169636)|
|Title:||Phase I Study of Panobinostat Plus ICE Chemotherapy Followed by A Randomized Phase-II Study of ICE compared with Panobinostat Plus ICE For Patients With Relapsed and refractory Classical Hodgkin Lymphoma|
|Principal Investigator:||Yasuhiro Oki|
|Treatment Agent:||Carboplatin; Etoposide; Ifosfamide; LBH589 "B" (oral) ; Panobinostat|
|Study Description:||The goal of this clinical research study is to learn if the combination of the |
drugs ifosfamide, carboplatin, and etoposide (a routine chemotherapy called
ICE) and panobinostat can help to control relapsed or refractory Hodgkin's
The safety of this drug combination will also be studied.